United Therapeutics Reports Record 2025 Revenue, Double-Digit Growth, Positive Outlook

summarizeSummary

United Therapeutics announced strong financial results for Q4 and full year 2025, with record revenues and double-digit growth in both revenue and diluted EPS, driven by key product sales and a positive outlook for clinical programs.

check_boxKey Events

• Record Full Year 2025 Revenues

  United Therapeutics reported record total revenues of $3.18 billion for 2025, an 11% increase over the previous year.

• Double-Digit EPS Growth

  Diluted earnings per share rose by 13.1% to $27.86 for the full year 2025.

• Strong Tyvaso DPI Sales

  Tyvaso DPI sales grew by 25% to $1.29 billion, contributing significantly to overall product revenue growth.

• Positive Clinical Pipeline Outlook

  Management anticipates "transformational growth" from upcoming pivotal data from ADVANCE OUTCOMES and TETON-1 clinical programs.

auto_awesomeAnalysis

This 8-K details the strong financial results for 2025, which were also reported in a concurrent 10-K filing. United Therapeutics achieved record revenues and double-digit growth in both revenue and diluted EPS, primarily driven by the robust performance of its Tyvaso DPI product. Management's optimistic outlook, including expectations for continued double-digit revenue growth and potential "transformational growth" from upcoming clinical trial data, signals a positive future. The significant reduction in litigation accruals and ongoing share repurchases further enhance the company's financial position and investor appeal.